PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to two standard immunotherapy drugs (ipilimumab and nivolumab) can reduce severe side effects while still fighting cancer. About 35 adults with advanced melanoma, non-small cell lung cancer, or bladder cancer will receive the combinatio…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:17 UTC
-
New hope for transplant patients with advanced skin cancer: immune drugs may control tumors without losing the kidney
Disease control OngoingThis early-phase study tests whether combining immune-boosting drugs (nivolumab and ipilimumab) with a transplant-protecting drug (tacrolimus) can shrink or control advanced skin cancers in kidney transplant recipients. The goal is to treat the cancer while keeping the donated ki…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Cholesterol drug could block melanoma spread in High-Risk patients
Prevention OngoingThis phase 2 trial tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvasta…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Prevention
Last updated May 13, 2026 16:04 UTC
-
Melanoma study aims to uncover hidden toll of immunotherapy
Knowledge-focused OngoingThis study looks at side effects and quality of life in people with melanoma who are getting immunotherapy after surgery. Researchers will track symptoms, blood markers, and how patients feel over two years. The goal is to learn more about why some people have side effects and ho…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 02:21 UTC
-
Facebook group aims to boost skin checks in young melanoma families
Knowledge-focused OngoingThis study tests whether a private Facebook group can help young adults (ages 18-39) diagnosed with early-stage melanoma and their close relatives do more skin checks and use better sun protection. About 1,160 participants from New Jersey, California, and Texas will join either a…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated May 07, 2026 18:38 UTC